^
Association details:
| Biomarker: | TERT promoter mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
Published date:
02/08/2021
Excerpt:
We identified 78 pts treated with ICI for aUC with available genomic profiling results…n univariable analysis there was a trend towards longer OS in pts with TERTp mutations (HR 0.53, 95% CI 0.27-1.06, p = 0.07), and shorter OS in pts with CDKN2B mutations (HR 1.91, 95% CI 0.98-3.73, p = 0.06)....The presence of a TERTp mutation was an independent predictor of improved OS in a cohort of aUC pts treated with ICI.
DOI:
10.1200/JCO.2021.39.6_suppl.476
Source:
Title:
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Excerpt:
...TERT promoter mutation had a particularly good prognosis with mOS of 21.1 months as compared with 7.5 months in all other patients (p=0.03)....The presence of a TERT promoter mutation was an independent predictor of improved OS in a cohort of aUC patients treated with an ICI
DOI:
10.1136/jitc-2020-002127
